Alzamend Neuro Reports Distinct Brain Profile for AL001 in Phase II Trial
Alzamend Neuro reports pharmacodynamic data showing AL001 may have a distinct brain interaction profile compared to lithium carbonate, with potential tolerability advantages. The Phase II trial analysis suggests AL001 affects key brain metabolites differently while maintaining lithium's core mechanism of action. Further confirmatory studies are planned to validate these initial findings.
Alzamend Neuro has reported encouraging pharmacodynamic findings from a brain magnetic resonance spectroscopy analysis conducted in healthy human subjects, suggesting its investigational treatment AL001 may interact with the brain in a distinct manner from lithium carbonate. The study assessed changes in five key brain metabolites across 18 brain regions when participants received two-weeks of blood bioequivalent and lithium-dose equivalent AL001 or lithium carbonate relative to baseline, with early data suggesting AL001 may work like lithium carbonate by selectively impacting brain chemicals where needed while leaving other healthy brain chemicals more undisturbed.
Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may generate a lower neurochemical footprint than lithium carbonate. Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action, with AL001 affecting this target in nearly twice as many brain regions (17 out of 18) as lithium carbonate (8 out of 18).
Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability. Glutamate was largely undisturbed in 10 of the 18 brain regions of patients after two-weeks of AL001, while two-weeks of lithium carbonate seemed to have caused disruptions to glutamate levels across every brain region measured.
These interpretations are based solely on qualitative review of all analyses and need to be further statistically confirmed in additional patient populations, the first of which is currently underway. Based on these initial findings, Alzamend has identified pharmacodynamic hypotheses to be tested in future confirmatory studies involving subjects with Alzheimer's, bipolar disorder type 1, major depressive disorder and post-traumatic stress disorder.
The company's CEO stated that lithium carbonate has been a cornerstone of psychiatric treatment for over 55 years, but its harsh side effect profile has always limited how widely and how long it can be used. These findings suggest AL001 may finally change that equation, delivering what lithium does best, without much of what makes it difficult to tolerate.